alexa Biosimilars: Review Of The Safety Issues And The Current Pharmacovigilance Methods
ISSN: 2329-6887

Journal of Pharmacovigilance
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Pharmacovigilance & Clinical Trials
October 27-29, 2014 Hyderabad International Convention Centre, India

Aashal B Shah
Posters: J Pharmacovigilance
DOI: 10.4172/2329-6887.S1.014
WHO defines biosimilar as ?A biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product.? They are copy versions of an approved original biologic medicine whose data protection has expired. Recent expiration of patents of the original biologic medicines has created opportunities for the development of biosimilars. Since biosimilars are available in the market at significantly lower costs compared to the conventional drugs, they are very important in developing countries like India. There are various sources of variation among the manufacturing process of original and the biosimilar drugs which can lead to considerable changes in the safety and efficacy of the biosimilar. A unique concern is their potential to induce an immune response. The other challenges related to biosimilars are naming/labelling, substitution and interchangeability and traceability. Moreover, since similar biologics are authorized based on a reduced preclinical and clinical data, clinical safety monitoring of these products should be stringent in post marketing phase to detect any unexpected adverse event at the earliest. Therefore, it has been made mandatory that biosimilar manufacturing companies should submit a Risk Management Plan (RMP) as a part of their marketing authorization process. Periodic Safety Update Reports (PSURs) may play an important role as a pharmacovigilance tool for biosimilars.
Aashal B Shah is currently pursuing MD Pharmacology (second year) in Government Medical College, Surat, affiliated to Veer Narmad South Gujarat University. Presently she is working on various projects related to Adverse Drug Reaction detection, monitoring, causality assessment, severity and preventability.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version